Replimune Group, Inc. is facing significantly more layoffs than initially reported. Between 161 and 224 Massachusetts employees are affected. This follows the FDA's second rejection of its lead cancer treatment, RP1. RP1 was an experimental therapy for advanced melanoma. Layoffs are occurring at facilities in Woburn and Framingham.
Woburn, Massachusetts
https://www.masslive.com/news/2026/04/mass-biotech-company-facing-between-161-and-224-layoffs-after-fda-rejects-dr-g-for-2nd-time.html